Douglas Yao
When administered to mice, PAC-3310 significantly reduces MK-801-induced hyperlocomotion, demonstrating that it has antipsychotic effects in vivo. Moreover, at doses up to 10x the effective dose, PAC-3310 produces none of the side effects typical of non-selective muscarinic agonists like xanomeline - no changes in salivation, urination, heart rate, etc. (5/7)